Author: Ravi Shankar

Press release – Neuilly-sur-Seine, Tuesday, September 22, 2026 – 5.45 pm

AutOnom®, when the sun cools the warehouses

As periods of extreme heat become more frequent and intense, thermal comfort in logistics buildings is taking on a new significance. For ARGAN, a building’s environmental performance cannot be separated from the quality of life of the people who work there.

With AutOnom® – the warehouse that generates its own energy – ARGAN has been developing a new generation of logistics warehouses since 2022, combining solar power generation, electricity storage and high-performance electric heat pumps.
Together, these systems enable AutOnom® occupiers to meet their heating and lighting needs using renewable energy generated on site. This approach now makes it possible to go one step further: the same heat pump that provides heating in winter can also cool workspaces in summer.

From heating to cooling: one system for every season

Traditionally, heating in French warehouses still relies heavily on gas-fired boilers. AutOnom® replaces this carbon-intensive system with reversible air-to-water electric heat pumps, which capture heat from the outside air to warm water in winter and reverse their cycle in summer to cool the warehouse via unit heaters.
The building thus becomes a fully-fledged energy infrastructure serving both its operations and its occupants.

Up to 13°C cooler inside the warehouse, even when outdoor temperatures exceed 35°C

This summer, three ARGAN sites benefited from these systems, including the Bain-de-Bretagne (35) facility operated by the teams at BSL, part of the DIMOTRANS Group. Céline Chatelain, QHSE and CSR Director at DIMOTRANS Group, was able to assess the system’s effectiveness throughout the summer:

“We pay particularly close attention to our employees’ working conditions. In a logistics facility, periods of extreme heat can quickly become a major concern. AutOnom® provides us with a practical solution, and we were able to see its benefits from the very first heatwaves in June. While outdoor temperatures reached 40°C, the temperature inside our warehouse remained at just 26–27°C. The difference was immediately noticeable for our teams.”

“We want to provide our employees with a high-quality working environment while reducing the environmental impact of our operations. AutOnom® enables us to pursue both objectives without having to choose between them.
The heat pump provides year-round comfort, both in winter and summer, while photovoltaic generation and energy storage allow us to manage our energy consumption intelligently, supported by the Building Management System (BMS) tools integrated with the AutOnom® equipment.
Finally, in a context of highly volatile energy prices, the AutOnom® solution gives us greater predictability and control over our energy costs. The electricity generated by the solar panels covers the building’s cooling needs using renewable energy produced directly on site. Overall, we are very satisfied with this solution.”

Thermal comfort is no longer a secondary consideration in a warehouse. It is a key factor in quality of life at work and, consequently, in the building’s overall performance

Stephane Cassagne, ARGAN’s Director of Development and Asset Management: “For occupiers, thermal comfort is gradually becoming an integral part of their quality-of-work-life policies. Against this backdrop, having a building capable of maintaining comfortable temperatures, including during periods of extreme heat that are expected to become more frequent, is becoming an increasingly important consideration.”

“With AutOnom®, ARGAN is championing a vision of logistics real estate in which a building’s performance is no longer measured solely by its size or storage capacity, but also by its energy efficiency and the comfort it provides to occupants. These factors are becoming increasingly important drivers of value for property companies’ real estate portfolios.

AutOnom® thus embodies a new generation of logistics real estate: a building that generates its own energy, stores it, uses it intelligently, and contributes to the well-being of its occupants.”

2026 financial calendar (Publication of the press release after closing of the stock exchange)

• October 1: Net sales of 3^rd quarter 2026
• November 20: General Assembly (WDP merger project)

2027 financial calendar (Publication of the press release after closing of the stock exchange)

• January 4: Net sales of 4^th quarter 2026
• January 21: Annual results 2026
• March 25: General Assembly 2027

About ARGAN

ARGAN is the only French real estate company specializing in the DEVELOPMENT & RENTAL OF PREMIUM WAREHOUSES listed on EURONEXT and is the leading player in its market in France. Building on a unique customer-centric approach, ARGAN develops PREMIUM and pre-let Au0nom® -labelled warehouses – i.e., which produce their own energy for self-consumption – for blue-chip companies, with tailor-made services throughout all project phases from the development milestones to the rental management. As at June 30, 2026, ARGAN represented a portfolio of 3.9 million sq.m, with close to 110 warehouses located in the continental area of France. Appraised at a total of €4.3 billion (excl. duties), this portfolio generates a yearly rental income of €224 million (yearly rental income based on the portfolio delivered as at June 30, 2026).
Profitability, well-mastered debt and sustainability are at the heart of ARGAN’s DNA. The financial solidity of the Group’s model is notably reflected in its Investment-grade rating (BBB- with a stable outlook) with Standard & Poor’s. ARGAN is also deploying a committed ESG policy addressing all its stakeholders. Achievements as part of this roadmap are regularly recognized by third-party agencies such as GRESB (rated: 83/100), Sustainalytics (low extra-financial risk), Ethifinance (gold medal) and Ecovadis (silver medal – top 15% amongst rated companies).
ARGAN is a listed real estate investment company (French SIIC), on Compartment A of Euronext Paris (ISIN FR0010481960 – ARG) and is included in the Euronext SBF 120, CAC All-Share, EPRA Europe and IEIF SIIC France indices.

www.argan.fr

Francis Albertinelli – CFO Aymar de Germay – General Secretary Samy Bensaid – Head of Investor Relations Phone: +33 1 47 47 47 40 E-mail: contact@argan.fr

Marlène Brisset – Media relations Phone: +33 6 59 42 29 35 E-mail: argan@cdrconsultancy.com

Attachment

• 20260922 – AutOnom – Heatpumps – Bain de Bretagne

Record Bookings in H1 2026

• Sharp rise in bookings: +112% to €5.16M in new annual recurring subscriptions (ARR), 20% above the amount signed for full-year 2025
• AI-native products: €1.02M in new ARR signed, representing 33% of the 2026 Q2 total

More Than 71% of Revenue Generated Outside France

• Revenue up sharply: +21%, including +26% for subscriptions at constant currency (+19% and +23% as reported)

Double-Digit Growth in Profitability

• EBIT: €5.7M, up 22% and 33% like-for-like (20.7% of revenue, versus 15.7% in H1 2025)
• Net income: €4.7M, up 15%
• Gross cash: €19.9M as of June 30, 2026
• Sovereign AI, from GPUs to the natural-language interface

Sidetrade, an AI-native company dedicated to Order-to-Cash, reported strong growth in both its business and its profitability in the first half of 2026. First-half revenue reached €34.8 million, up 21% at constant currency (19% as reported), while EBIT rose 22% to €5.7 million and net income increased 15% to €4.7 million. This performance comes as Sidetrade accelerates its technology investment to provide customers with sovereign AI across the full stack, from its private cloud and its GPUs through to the natural-language interface for the end user.

Sidetrade (in millions of euros)	H1 2026	H1 2025	Change
Revenue	34.8	29.3	+19%
of which Subscriptions	31.3	25.4	+23%
Gross margin	25.7	22.6	+14%
as % of first-half revenue	74%	77%
EBIT*	5.7	4.6	+22%
as % of first-half revenue	16.2%	15.7%
Net income	4.7	4.1	+15%

2026 figures are unaudited consolidated data, approved by the Board of Directors on July 7, 2026.
* EBIT is operating income under French GAAP, including the Research Tax Credit (CIR).

Olivier Novasque, CEO and Founder of Sidetrade, stated:

“In the enterprise world, the question is no longer which AI model is best. It is which environment runs a company’s AI agents most effectively, for each use case, while upholding its standards of security, governance, and cost control. Let us be clear. It is by answering these legitimate demands with precision that AI deployment becomes a decisive competitive advantage, and delivers the expected return on investment. No serious finance department will deploy autonomous agents at scale with a general-purpose AI provider, without guarantees on governance or on production cost, in a market where the token price is likely to soar. That is exactly what we have built at Sidetrade for our customers: control of the full AI stack.. Our private cloud runs on its own GPU compute capacity, which secures data protection, visibility, and control over production costs. Our Data Lake consolidates nearly $10 trillion in B2B payment experiences, a strategic asset no Frontier Lab holds, one that enables us to train proprietary Order-to-Cash models and to pair them with open-source models. And our SAFE framework enforces security, governance, and the selection of the most cost-effective model for each agent and each use case. This end-to-end command is what separates a lasting competitive advantage from the technological trials that so frequently disappoint at scale.

In the first half of 2026, the record bookings speak for themselves. We won nearly all of the competitive tenders we entered, across every region, because we own the entire stack behind our AI-native products. We have every reason to believe this trajectory will continue in the months ahead. We control the data that feeds the intelligence, the models that produce it, the GPUs that run it, and the rules that govern how it acts. No prompt, no document, no customer data ever leaves our private cloud to be processed by a third-party model at a hyperscaler or a Frontier Lab. Our execution costs do not depend on the token prices of one provider, or several stacked in a chain.

On a like-for-like basis, excluding ezyCollect by Sidetrade, our gross margin improved from 77% to 78.4% in the first half. At the same time, we began deploying our own AI across every department, and the operating leverage is already evident. Despite the expected impact of ezyCollect by Sidetrade, our EBIT rose 22% over the period and reached 20.7% of revenue on a like-for-like basis, against 15.7% in the first half of 2025, a gain of 500 basis points in a single year. AI sovereignty is not judged by the provider’s nationality, nor by a data-protection guarantee alone. It is command of the entire AI stack, from the models to the compute to a predictable production cost, that allows any finance department to invest in AI at scale without the risk of losing control. That is the sovereignty we extend to our customers and to which we hold ourselves.”

Record Bookings in H1 2026

Bookings	H1 2026	Change vs H1 2025
New annual recurring subscriptions (ARR)	€5.16 million	+112%
Annual Contract Value (ACV)	€9.30 million	+58%
Total Contract Value (TCV)	€18.71 million	+194%

A breakdown by region, channel, and quarter can be found in the July 21, 2026 press release.

With €5.16 million in new annual recurring subscriptions (ARR) in the first half of 2026, up 112%, Sidetrade already exceeds its full-year 2025 total by 20%.

The bookings mix is shifting toward new customers in the first half of 2026. New Business now accounts for 56% of the total, up from 30% a year earlier, and the average initial commitment period lengthened from 44.5 to 48.8 months. Sidetrade is signing more new customers, on longer contracts.

North America accounted for 44% of first-half bookings for 2026, but only 27% of subscription revenue. This gap illustrates the region’s future growth potential.

Contracts signed in the first half of 2026 will begin to contribute more significantly to revenue from the fourth quarter of 2026. Total Contract Value (TCV) of signed contracts reached €18.71 million (up 194%), 53% above the full-year 2025 total. These contracts represent committed business that will be recognized as revenue over the coming years.

AI-Native Products: 33% of Bookings at Launch

Three months after launching its new generation of products, Sidetrade’s shift to AI-native is delivering early commercial traction. In the second quarter of 2026, Aimie Cash Collection Agent, Agent Builder Studio, and Aimie IQ generated €1.02 million in ARR, representing 33% of the €3.11 million in new ARR signed during the period. In total, 80 AI agents were placed on firm order, including 26 Aimie Agents and 54 Customer Agents. Agent Builder Studio enables customers and their partners to design their own agents, while Aimie IQ provides natural-language access to Sidetrade’s intelligence and orchestration capabilities.

These new AI-native offerings are sold as subscriptions that include set volume of tasks performed by the agents and “O2C IQ,” Sidetrade’s proprietary consumption unit for measuring generative AI usage. Customers therefore gain visibility into their AI costs without exposure to fluctuations in third-party token pricing.

Following this initial commercial phase, Agent Builder Studio and Aimie IQ are scheduled to enter production with beta customers in the fourth quarter of 2026.

Strong H1 2026 Revenue Growth: +21% at Constant Currency, Driven by Subscriptions up 26%
Sidetrade generated €34.8 million in revenue in the first half of 2026, up 19% as reported and 21% at constant currency. Subscription revenue grew faster, up 23% as reported and 26% at constant currency, to €31.3 million. Subscriptions now account for 90% of Group revenue.

This growth includes ezyCollect by Sidetrade, consolidated since the fourth quarter of 2025. Excluding ezyCollect by Sidetrade, organic subscription revenue grew 6%, reflecting the lower level of bookings recorded in 2025. The strong rebound in bookings since the start of 2026 is expected to begin contributing to revenue growth in the fourth quarter of 2026, with a progressively greater impact through 2027.

In the first half of 2026, more than 71% of Group revenue was generated outside France, while 73% of subscription revenue came from international markets. North America is now the Group’s largest region for subscriptions, accounting for just over 27% of subscription revenue, ahead of France. Asia-Pacific accounted for 16% of the total, driven by the integration of ezyCollect by Sidetrade.

Double-Digit Growth in Profitability

• Robust gross margin at 74% of revenue (78.4% like-for-like): up 14%

In a still-demanding macroeconomic environment, gross margin totaled €25.7 million in the first half of 2026, up €3.1 million from the first half of 2025. The overall gross margin rate was 74% of consolidated first-half revenue (versus 77% a year earlier). On a like-for-like basis (excluding ezyCollect by Sidetrade), it reached 78.4% (up 1.4 points from H1 2025) and held steady at 89% for subscriptions, confirming the structural resilience of the Company’s model.

• EBIT up sharply: up 22% (up 33% like-for-like)

EBIT reached €5.7 million in the first half of 2026, up 22% from €4.6 million in H1 2025, or 16.2% of first-half revenue (versus 15.7% a year earlier). On a like-for-like basis (excluding ezyCollect by Sidetrade), EBIT rose 33% with EBIT margin reaching 20.7% of first-half revenue, a gain of nearly 5 points from the first half of 2025.

This record like-for-like profitability demonstrates operating leverage in full effect. In a tight market where companies remain cautious about investment, Sidetrade drew on the momentum of its recurring revenue while cutting operating expenses by €1 million over the period. That cost discipline, particularly in R&D (helped by AI), sales and marketing, drove stronger operating efficiency.

The first-half 2026 operating margin also includes a €1.9 million research tax credit (CIR),versus €1.7 million in H1 2025, and a limited capitalization of R&D costs (€0.15 million, representing 2% of H1 2026 R&D expenditures).

Ultimately, the rise in EBIT to 16.2% (21% on a like-for-like basis, versus 16% in the first half of 2025) reflects continued gains in operating efficiency and a new profitability threshold.

First-Half Net Income up 15% to €4.7 million
The Group’s net financial result, close to zero in the first half of 2026 (versus €0.1 million in H1 2025), mainly reflects interest income from the short-term cash investments was largely offset by interest on borrowings.

Corporate income tax charge is estimated at €0.9 million for the first half of 2026, slightly higher than the €0.6 million recorded in the same period a year earlier, in line with the improvement in operating performance.

Overall, Sidetrade’s net income rose 15% to €4.7 million in the first half of 2026. The increase marks a new profitability milestone and confirms the Group’s ability to grow revenue and improve profitability at the same time, despite a challenging economic environment.

A Cash-Generative Model
In the first half of 2026, Sidetrade generated operating cash flow of €9.1 million (excluding the CIR timing impact), up sharply from €5.4 million in H1 2025 (excluding the CIR timing impact).

As of June 30, 2026, Sidetrade held gross cash of €19.9 million, up €3.6 million from December 31, 2025, excluding the calendar effect tied to the CIR refund. The Group also held 84,946 treasury shares, valued at €14.8 million as of June 30, 2026.

Financial debt stood at €28.0 million at the end of June 2026, mainly linked to financing the acquisition of ezyCollect by Sidetrade through a €25 million seven-year loan at 3.1%.

Sidetrade retains the flexibility to fund its investments and support its expansion, while maintaining a robust balance sheet.

Full Control of the AI Stack, from GPUs to the Natural-Language Interface
Sidetrade has built an integrated AI infrastructure that puts the five layers required to run its agents under its control (data, models, compute capacity, execution environment, and autonomous agents).

At the core of this infrastructure is Sidetrade’s proprietary Order-to-Cash Data Lake, which has aggregated $10 trillion in B2B transactions across 45 million buyer companies since 2015. It feeds specialized Order-to-Cash models that combine open-weight large language models fine-tuned by Sidetrade with its own predictive models for payment behavior, buyer risk, and the next best collection action.

These models run on Sidetrade’s own GPU compute (mainly NVIDIA H100 and H200 processors), inside its private cloud and interconnected data centers on both sides of the Atlantic. Sidetrade therefore controls the entire technical chain, from model training to execution, without relying on an external generative model provider. No customer prompt, document, or data leaves its private environment.

This control now extends to how agents act. Launched on September 10, 2026 (see press release), SAFE, the Sidetrade Agentic Framework for Enterprise, is the common execution layer across the Group’s AI-native products. SAFE selects the model suited to each task, governs agent autonomy, logs their actions, and triggers a deterministic escalation when human intervention is required. The infrastructure is certified ISO 27001, SOC 1 Type II, and SOC 2 Type II. Agents are validated against the OWASP Agentic Top 10 before going into production.

This end-to-end control also extends to the economics of its AI. The Group produces the consumption units of its generative intelligence, “O2C IQ,” on its own infrastructure, without depending on any third party’s per-million-token pricing.

On June 30, 2026, The Hackett Group® awarded Sidetrade its 2026 Innovation Award in the Technology Operations category, following an evaluation of demonstrated results (see press release).

The targets set out in the O2C Intelligence 2030 plan, published on April 7, 2026, are unchanged: more than 50% of revenue from AI-native products by 2030.

Next financial announcement
Third Quarter 2026 Revenue: October 20, 2026 (after stock market close)

Investor relations @Sidetrade
Christelle Dhrif                 00 33 6 10 46 72 00           cdhrif@sidetrade.com

Media relations @Sidetrade
Oli Thornton                     00 44 7933 108 107           oli.thornton@sidetrade.com

About Sidetrade (www.sidetrade.com)
Sidetrade (Euronext Growth: ALBFR.PA) is an AI-native company dedicated to Order-to-Cash (O2C). Its platform combines O2C-dedicated applications, autonomous AI agents, and Aimie IQ, an intelligent natural-language interface that helps enterprises accelerate their cash generation, all built on SAFE, the Sidetrade Agentic Framework for Enterprise. Sidetrade operates the world’s largest proprietary O2C Data Lake: nearly $10 trillion in B2B transactions and close to 45 million buying companies. This data is used to train specialized AI models that monitor, analyze, decide, and act autonomously throughout the O2C cycle. Sidetrade supports companies in 85 countries with 450 employees across Europe, North America, and Asia-Pacific.

For more information, visit www.sidetrade.com and follow @Sidetrade on LinkedIn.

In the event of any discrepancy between the French and English versions of this press release, only the French version is to be taken into account.

Attachment

• Double-Digit Growth in Profitability in FYH 2026

As stated in paragraph 6 in General Terms of Auction for Treasury bonds, the Government Debt Management offered the equivalent of 10% of the nominal value sold in the auction 18. September, at the price of accepted bids.

Series	RIKB 38 0215	RIKS 50 0915
ISIN	IS0000037265	IS0000037794
Additional issuance (nominal)	120,000,000	224,000,000
Settlement date	09/23/2026	09/23/2026
Total outstanding (nominal)	93,129,700,000	45,391,020,947

Regulated Information

Nyrstar NV: Publication of First Half 2026 Accounts

22 September 2026 at 17:30 CET

Nyrstar NV today advises that it has published its unaudited accounts for H1 2026 on the website of Nyrstar NV (www.nyrstarnv.be).

About Nyrstar NV
The Company is incorporated in Belgium and listed on Euronext Brussels under the symbol NYR. For further information please visit the Nyrstar NV website: www.nyrstarnv.be

For further information contact:

Company Secretary     company.secretary@nyrstarnv.be

Attachment

• H1-2026 accounts publication EN

Press release – No. 17 / 2026

Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity

• The Phase 3 initiation marks a defining step toward establishing petrelintide as a future first-choice therapy for millions of people living with overweight or obesity
• The global Phase 3a ZUPREME program consists of three trials, designed to support marketing applications for petrelintide monotherapy in chronic weight management
• The Phase 3a program builds on positive Phase 2 results, which demonstrated double-digit weight loss with a tolerability profile largely comparable to placebo, supporting petrelintide’s potential to redefine the weight management experience for people living with obesity or overweight

Copenhagen, Denmark, September 22, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces the initiation of the global registrational Phase 3 ZUPREME program, evaluating the efficacy and safety of once-weekly petrelintide versus placebo in people with overweight or obesity.

The Phase 3a program for petrelintide monotherapy, which is being conducted with Zealand Pharma’s partner Roche, consists of three trials: ZUPREME-3, ZUPREME-4, and ZUPREME-5, evaluating the efficacy and safety of once-weekly petrelintide versus placebo in people with obesity or overweight without type 2 diabetes, people with obesity or overweight with type 2 diabetes, and people with obesity or overweight and established cardiovascular disease, respectively. The three trials are expected to enroll approximately 7,000 participants in total.

“The Phase 3a program is designed to confirm the first-choice potential of petrelintide – supported by the data we have seen throughout the clinical trials with petrelintide: clinically meaningful double-digit weight reduction and a tolerability profile that supports the long-term adherence that chronic weight management requires,” said David Kendall, MD, Chief Medical Officer at Zealand Pharma. ”The program is designed to generate the robust, longer-term evidence needed to support regulatory filings and bring petrelintide to the millions of people demanding a better weight management experience.”

About the Phase 3a ZUPREME program
ZUPREME-3 is a randomized, double-blind, placebo-controlled, Phase 3 trial, evaluating the efficacy and safety of once-weekly petrelintide compared with placebo in participants living with overweight (BMI ≥ 27 < 30 kg/m²) or obesity (BMI ≥ 30 kg/m²) with at least one weight-related comorbidity without type 2 diabetes (T2D). The trial will enroll a total of approximately 3,900 participants.

ZUPREME-4 is a randomized, double-blind, placebo-controlled, Phase 3 trial, evaluating the efficacy and safety of once-weekly petrelintide compared with placebo in participants living with overweight or obesity and T2D. The trial will enroll a total of approximately 600 participants.

The ZUPREME-3 and ZUPREME-4 trials include a screening period, a dose escalation period of 12 weeks followed by a maintenance period until week 64, and a safety follow-up period after treatment is completed until week 77. All participants who complete the week 64 visit will be eligible to continue in an optional open-label extension (OLE) study. Participants in the OLE study will be offered treatment with petrelintide regardless of which treatment arm they were allocated in the main study.  

ZUPREME-5 is a randomized, double-blind, placebo-controlled, Phase 3 trial, evaluating the efficacy and safety of once-weekly petrelintide in participants living with overweight or obesity and established cardiovascular disease (CVD) with or without T2D.  ZUPREME-5 includes a screening period, a dose escalation period of 12 weeks followed by a maintenance period, with the primary efficacy assessment occurring at week 64. Following the primary assessment, participants continue into an event-maintenance phase. The trial can last up to a total of 3 years and will enroll a total of approximately 2,500 participants.

The primary endpoint in the Phase 3 ZUPREME trials is percentage change in body weight from baseline to week 64. Secondary endpoints include, but are not limited to, change in waist circumference, HbA1c, cardiometabolic risk factors, physical functioning, and change in eating behaviors.

About petrelintide
Petrelintide is a long-acting amylin analog suitable for once-weekly subcutaneous administration that has been designed with chemical and physical stability with no fibrillation around neutral pH, allowing for co-formulation and co-administration with other peptides¹. Human amylin is produced in the pancreatic beta cells and co-secreted with insulin in response to ingested nutrients. Amylin receptor activation has been shown to reduce body weight by restoring sensitivity to the satiety hormone leptin^2,3, inducing a sense of feeling full faster.

In 2025, Zealand Pharma and Roche entered into an exclusive collaboration and licensing agreement to co-develop and co-commercialize petrelintide for people living with overweight and obesity. Petrelintide is currently being developed for chronic weight management as both a monotherapy agent and in combination with Roche’s GLP-1/GIP receptor dual agonist enicepatide (CT-388). A Phase 2 trial evaluating the combination of petrelintide and enicepatide (CT-388) is planned for initiation in the second half of 2026.

About Zealand Pharma
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.

To date, more than ten Zealand Pharma invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.

Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Cambridge, Massachusetts. Learn more at www.zealandpharma.com.

Forward looking statements
This press release contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma’s expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products, the timing of the company’s pre-clinical and clinical trials and the reporting of data therefrom. These forward-looking statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would” and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events, patient recruitment or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems at third party manufacturers; dependency on third parties, for instance contract research or development organizations; unexpected growth in costs and expenses; our ability to affect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this company announcement and are based on information available to Zealand Pharma as of the date of this announcement. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

Contacts
Eric Rojas (Investors)
Vice President, Head of Investor Relations
Zealand Pharma
Email: erojas@zealandpharma.com

Neshat Anis Ahmadi (Investors) 
Investor Relations Manager 
Zealand Pharma 
Email: neahmadi@zealandpharma.com

Rachel James-Owens (Media) 
Vice President, Corporate Communications & Media Relations 
Zealand Pharma 
Email: rjamesowens@zealandpharma.com  

Andreas Hylleberg Mølleskov (Media)  
Director, External Communications 
Zealand Pharma 
Email: ahylleberg@zealandpharma.com  

Amber Fennell, Jessica Hodgson, Sean Leous (Media) 
ICR Healthcare 
Email: zealandpharma@icrhealthcare.com  
+44 (0) 7739 658 783 

References
1. Eriksson et al. Presentation at ObesityWeek, November 1–4, 2022, San Diego, CA. Link: https://www.zealandpharma.com/media/0gnfxg4b/zp8396-sema-coformulation-obesityweek-2022.pdf.
2. Mathiesen et al. Eur J Endocrinol 2022;186(6):R93–R111.
3. Roth et al. Proc Natl Acad Sci U S A 2008;105(20):7257–7262

US$367 Million, 360 MW Solar Project to Supply Data Centre for 25 Years; Tadaa targets US$7.3 Million in Annual Revenue

KUALA LUMPUR, Malaysia, Sept. 22, 2026 (GLOBE NEWSWIRE) — Treasure Global Inc. (NASDAQ: TGL) (“Treasure Global” or the “Company”), a Southeast Asia–anchored technology company focused on AI-powered enterprise solutions and digital transformation, today announced that its subsidiary, Tadaa Technology Sdn Bhd (“Tadaa”), has entered into a strategic partnership with Kainan Sdn Bhd (“Kainan”) to provide AI-enabled technology solutions for a proposed US$367 million solar farm development spanning approximately 1,000 acres with a planned capacity of 360 megawatts (“MW”). The project is intended to supply renewable energy to a data centre under a 25-year power supply arrangement.

The project marks Tadaa’s expansion into large-scale renewable-energy technology and provides a long-term commercial framework for the deployment. Upon full deployment, Tadaa is targeting approximately US$7.3 million in annual technology-related revenue from the project.

Under the partnership, Tadaa will provide the AI-powered digital backbone for the solar farm, integrating IoT-enabled infrastructure, intelligent energy management, real-time performance monitoring, data analytics, predictive maintenance, system integration and secure cloud infrastructure. The technology is intended to support reliable, efficient and data-driven management of renewable-energy generation.

“This initiative represents an important step in extending our AI and technology capabilities into large-scale renewable-energy infrastructure,” said Sam Teo, Acting Chief Executive Officer of Treasure Global. “The 360 MW project, supported by a 25-year power supply arrangement for a data centre, provides Tadaa with an opportunity to establish a strong track record in AI-enabled energy management. As data-centre energy demand and renewable-energy infrastructure continue to grow, we believe intelligent monitoring, analytics and predictive capabilities will become increasingly important in improving asset performance, operational efficiency and the reliability of large-scale renewable-energy infrastructure.”

The project positions Treasure Global within one of the world’s fastest-growing energy markets. Global solar PV capacity increased from approximately 710 GW in 2020 to 1,865 GW by the end of 2024, while global investment in solar PV was expected to reach approximately US$450 billion in 2025, according to the International Energy Agency (“IEA”), underscoring the scale of the market opportunity for technology-enabled solar infrastructure.

Malaysia is also accelerating its renewable-energy transition under the National Energy Transition Roadmap (“NETR”), which targets renewable energy accounting for 40% of installed capacity by 2035 and 70% by 2050. The upcoming Large-Scale Solar 6 (“LSS6”) program is expected to add approximately 2,650 MW of new capacity, highlighting the growing domestic pipeline for renewable-energy technology and energy-management solutions.

The initiative also aligns with the global transition toward cleaner energy infrastructure and growing environmental, social and governance (“ESG”) priorities, while extending Treasure Global’s AI and technology capabilities into a high-growth infrastructure sector.

Treasure Global views the 360 MW project as a potential foundation for further expansion into renewable-energy technology serving energy-intensive infrastructure. The Company intends to leverage the deployment as a reference for future solar, data-centre energy and clean-energy opportunities in Malaysia and across Southeast Asia, creating potential for additional recurring technology revenue and long-term growth.

Kainan is a Malaysia-based renewable energy company established in 2007, specializing in the development of solar energy projects and participating in Malaysia’s Corporate Renewable Energy Supply Scheme (CRESS).

About Treasure Global:
Treasure Global is a Malaysia-based technology solutions provider specializing in innovative platforms that drive digital transformation in retail and services. The Company’s flagship product is the ZCITY Super App, which integrates e-payment solutions with customer loyalty rewards to create a seamless online-to-offline user experience. As of March 31, 2026, ZCITY has attracted 2.71 million registered users, positioning Treasure Global as a key player in Malaysia’s digital economy. Treasure Global continuously leverages cutting-edge technologies, including artificial intelligence and data analytics, to enhance its platform’s capabilities across e-commerce, fintech, and other verticals.

Visit treasureglobal.org for more information.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements reflect the Company’s current expectations, assumptions, and projections about future events and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking statements typically include terminology such as “anticipates,” “believes,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” or similar expressions.

Factors that could cause actual results to differ materially include, without limitation, the development and completion of the proposed solar project; achievement of the planned 360 MW capacity; performance and duration of the contemplated power supply arrangement; Tadaa’s ability to deploy and commercialize its AI-enabled technology solutions; achievement of targeted annual revenue; project financing and execution; regulatory and permitting requirements; technology performance; data-centre power demand; cybersecurity and data privacy risks; changes in renewable-energy policies; and broader economic and energy-market conditions.

The forward-looking statements in this press release speak only as of the date hereof. The Company assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

CONTACT
Investor and media contact:
Investor Relations Team
Treasure Global
ir_us@treasureglobal.org

FORM 8.3

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.      KEY INFORMATION

(a)   Full name of discloser	Davidson Kempner Capital Management LP
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offeree	DCC plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
(e)   Date position held/dealing undertaken For an opening position disclosure, state the latest practicable date prior to the disclosure	21/09/2026
(f)   In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”	No

2.      INTERESTS AND SHORT POSITIONS

If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)

Class of relevant security (Note 3)	€0.25 Ordinary Shares (ISIN – IE0002424939)
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled
(2)   Cash-settled derivatives	1,481,400	1.73%
(3)   Stock-settled derivatives (including options) and agreements to purchase/ sell
Total	1,481,400	1.73%

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3.      DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)      Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit (Note 5)

(b)      Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing	Number of reference securities (Note 6)	Price per unit
€0.25 Ordinary Shares	CFD	Decreasing a long position	(120,000)	GBP 64.3000
€0.25 Ordinary Shares	CFD	Decreasing a long position	(73,972)	GBP 64.3500

(c)      Stock-settled derivative transactions (including options)

(i)      Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates (Note 6)

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)      Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit (Note 5)

(d)      Other dealings (including transactions in respect of new securities) (Note 3)

Class of relevant security

Nature of dealing e.g. subscription, conversion, exercise

Details

Price per unit (if applicable) (Note 5)

4.      OTHER INFORMATION

(a)      Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer. Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b)      Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

(c)        Attachments

Is a Supplemental Form 8 attached?

NO

Date of disclosure	22/09/2026
Contact name	Alex McMillan
Telephone number	646 282 5805

Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

NOTES ON FORM 8.3

1.      See the definition of “connected fund manager” in Rule 2.2 of Part A of the Rules.

2.      See the definition of “interest in a relevant security” in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.

3.      See the definition of “relevant securities” in Rule 2.1 of Part A of the Rules.

4.      See the definition of “dealing” in Rule 2.1 of Part A of the Rules.

5.      If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.

6.      See Rule 2.5(d) of Part A of the Rules.

7.      If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Marimekko Corporation, Press release, 22 September 2026 at 5.15 p.m. EEST

Marimekko and VEJA announce limited-edition collaboration collection launching in November 2026

Leading Finnish lifestyle design house Marimekko and French footwear brand VEJA launch a limited-edition collaboration collection combining Marimekko’s world-renowned art of printmaking with VEJA’s signature sneaker styles. The collaboration features two VEJA sneaker models — the Salar for adults and the Small Canary for kids — adorned with Marimekko’s floral Popkorni print designed by Antti Kekki.

“The VEJA x Marimekko collaboration combines joy and functionality with Marimekko’s playful Popkorni print interpreted in VEJA’s iconic sneaker styles. Both Marimekko and VEJA share a commitment to thoughtful and long-lasting design, and I trust that this collaboration will delight our communities around the world,” says Rebekka Bay, Creative Director, Marimekko.

“We are proud to collaborate with Marimekko — an iconic house with a singular vision, renowned for its mastery of prints and bold colors, and its unique ability to give artists a true space for expression. We share the same deep care for the human behind every product, refined materials, and craftsmanship,” says Caroline Bulliot Krivanek, Art Director, VEJA.

The featured Marimekko print, Popkorni, is a joyful and playful floral motif designed by Finnish artist Antti Kekki in 2024. The cheerful shapes, created by Kekki through paper-cutting, resemble little fluttering flowers whose lively movement evokes parties brimming with life and sound. The Finnish name of the design means “popcorn”.

The VEJA x Marimekko limited-edition collection will be available from 12 November 2026 onwards.

Download photos

Further information:
Leena Salomaa, Marimekko Communications
Tel. +358 9 758 7233
leena.salomaa@marimekko.com

DISTRIBUTION:
Key media

About Marimekko
Marimekko is a Finnish lifestyle design company renowned for its original prints and colors. The company’s product portfolio includes high-quality clothing, bags and accessories as well as home décor items ranging from textiles to tableware. When Marimekko was founded in 1951, its unparalleled printed fabrics gave it a strong and unique identity. In 2025, the company’s net sales totaled EUR 190 million and comparable operating profit margin was 17.1 percent. Globally, there are over 170 Marimekko stores, and online store serves customers in 39 countries. The key markets are Northern Europe, the Asia-Pacific region and North America. The Group employs about 490 people. The company’s share is quoted on Nasdaq Helsinki Ltd. www.marimekko.com 

About VEJA
Founded in 2004 by Sébastien Kopp and François-Ghislain Morillion, VEJA makes sneakers differently, combining social projects, economic justice, and ecological materials.  Designed in France and made in Brazil, VEJA sneakers use organic cotton, wild Amazonian rubber, traceable leather, and recycled PET, paying producers up to five times the market price. The brand has expanded to sandals and performance shoes. Since 2020, the Cobbler Project has repaired over 55,000 pairs, all types and brands combined. VEJA employs 600 people, is present in 100+ countries, and works with 4,000+ retailers.  

MONTREAL, Sept. 22, 2026 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor“ or the “Corporation“) announced today that its Board of Directors has approved a monthly dividend of C$0.01333 per common share (C$0.16 annually) for October 2026. This will be payable on October 19, 2026, to shareholders of record as of the close of business on October 9, 2026.

The Corporation’s monthly dividend qualifies as an “eligible dividend” for Canadian income tax purposes. The payment and increase of dividends are at the discretion of the Board and will depend on the Corporation’s financial results, cash requirements, prospects and other factors deemed relevant by the Board.

About Dynacor

Dynacor Group is an ore processing company dedicated to producing gold sourced from artisanal miners. Since its establishment in 1996, Dynacor has pioneered a responsible mineral supply chain with stringent traceability and audit standards for the fast-growing artisanal mining industry. By focusing on formalized miners, the Canadian company offers a win-win approach for governments and miners globally. Dynacor operates the Veta Dorada plant and owns a gold exploration property in Peru. The company is expanding to West Africa and within Latin America.

The premium paid by luxury jewellers for Dynacor’s PX Impact® gold goes to Fidamar Foundation, an NGO that mainly invests in health and education projects for artisanal mining communities in Peru. Visit www.dynacor.com for more information.

Forward-Looking Information

Certain statements in the preceding may constitute forward-looking statements, which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Dynacor, or industry results, to be materially different from any future result, performance or achievement expressed or implied by such forward-looking statements. These statements reflect management’s current expectations regarding future events and operating performance as of the date of this news release.

Contact:

For more information, please contact:

Ruth Hanna
Director, Investor Relations
T: 514-393-9000 #236

E: investors@dynacor.com
Website: https://dynacor.com

Renmark Financial Communications Inc.
Bettina Filippone
T: (416) 644-2020 or (212) 812-7680
E: bfilippone@renmarkfinancial.com  
Website: www.renmarkfinancial.com

WARSAW, Indiana, Sept. 22, 2026 (GLOBE NEWSWIRE) — Lake City Bank, the single bank subsidiary of Lakeland Financial Corporation (Nasdaq: LKFN), announced it was named to the Piper Sandler Sm-All Stars Class of 2026, which recognizes the top performing small-cap banks and thrifts across the United States. Lake City Bank was among only 25 institutions recognized nationwide and was the only bank headquartered in Indiana to make the list.

Piper Sandler analyzes all publicly traded banks and thrifts with a market capitalization below $2.5 billion and evaluates institutions based on seven financial variables. Recognized institutions significantly outperformed industry medians in earnings growth, loan growth, deposit growth and return on average equity, while also meeting rigorous standards for asset quality and capital levels over the last 12 months based on data at June 30, 2026.

“The Lake City Bank team’s focus on taking care of our communities and clients has proven to also benefit our shareholders. Our inclusion on the Piper Sandler Sm-All Stars list reflects our consistent execution and performance over a long period of time,” commented David Findlay, Chairman and Chief Executive Officer.

This marks the fourth time that Lake City Bank has been recognized on the annual Piper Sandler Sm-All Stars list.

Lake City Bank, a $7.2 billion bank headquartered in Warsaw, Indiana, was founded in 1872 and serves Central and Northern Indiana communities with 55 branch offices and a robust digital banking platform. Lake City Bank’s community banking model prioritizes building in-market long-term customer relationships while delivering technology-forward solutions for retail and commercial clients. The bank is the single bank subsidiary of Lakeland Financial Corporation (Nasdaq Global Select/LKFN). For more information visit www.lakecitybank.com.

Contact
Luke Weick
First Vice President
Marketing Manager
(574) 267-9198 x47279 office
(260) 431-7061 mobile
luke.weick@lakecitybank.com